CoChat

Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple Myeloma

Chinen, Yoshiaki, Kuroda, Junya, Shimura, Yuji, Nagoshi, Hisao, Kiyota, Miki, Yamamoto-Sugitani, Mio, Mizutani, Shinsuke, Sakamoto, Natsumi, Ri, Masaki, Kawata, Eri, Kobayashi, Tsutomu, Matsumoto, Yosuke, Horiike, Shigeo, Iida, Shinsuke, Taniwaki, Masafumi · 2014 · Cancer Research
Cited by 36

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Multiple myeloma is a cytogenetically/molecularly heterogeneous hematologic malignancy that remains mostly incurable, and the identification of a universal and relevant therapeutic target molecule is essential for the further development of therapeutic strategy. Herein, we identified that 3-phosphoinositide–dependent protein kinase 1 (PDPK1), a serine threonine kinase, is expressed and active in all eleven multiple myeloma–derived cell lines examined regardless of the type of cytogenetic abnormality, the mutation state of RAS and FGFR3 genes, or the activation state of ERK and AKT. Our results revealed that PDPK1 is a pivotal regulator of molecules that are essential for myelomagenesis, such as RSK2, AKT, c-MYC, IRF4, or cyclin Ds, and that PDPK1 inhibition caused the growth inhibition and the induction of apoptosis with the activation of BIM and BAD, and augmented the in vitro cytotoxic effects of antimyeloma agents in myeloma cells. In the clinical setting, PDPK1 was active in myeloma cells of approximately 90% of symptomatic patients at diagnosis, and the smaller population of patients with multiple myeloma exhibiting myeloma cells without active PDPK1 showed a significantly less frequent proportion of the disease stage III by the International Staging System and a significantly more favorable prognosis, including the longer overall survival period and the longer progression-free survival period by bortezomib treatment, than patients with active PDPK1, suggesting that PDPK1 activation accelerates the disease progression and the resistance to treatment in multiple myeloma. Our study demonstrates that PDPK1 is a potent and a universally targetable signaling mediator in multiple myeloma regardless of the types of cytogenetic/molecular profiles. Cancer Res; 74(24); 7418–29. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-14-1420

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 36

Metadata

Authors
Chinen, Y., Kuroda, J., Shimura, Y., Nagoshi, H., Kiyota, M., Yamamoto-Sugitani, M., Mizutani, S., Sakamoto, N., Ri, M., Kawata, E., Kobayashi, T., Matsumoto, Y., Horiike, S., Iida, S., & Taniwaki, M.
Venue
Cancer Research
Published
2014-12-14
Volume
74
Issue
24
Pages
7418-7429
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2012902797
Cited by
36
References
9
FWCI
3.06
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple Myeloma. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-1420
The paper
Chinen, Y., Kuroda, J., Shimura, Y., Nagoshi, H., Kiyota, M., Yamamoto-Sugitani, M., Mizutani, S., Sakamoto, N., Ri, M., Kawata, E., Kobayashi, T., Matsumoto, Y., Horiike, S., Iida, S., & Taniwaki, M. (2014). Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple Myeloma. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-1420

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.